G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and exciting — the football game was interesting, yes? — because that oh-so-familiar routine of meetings, deadlines, and what-not has predictably returned. We are quite busy already quaffing cups of stimulation and munching on egg sandwiches. Feel free to join us. Meanwhile, here is your menu of tidbits. Hope you have a smashing day and please do keep in touch …

Sanofi (SNY) declined demands by some Philippines lawmakers to refund the full cost of purchasing its dengue vaccine or support an indemnification fund for those families who may seek damages, ABS-CBN News reports. Sanofi argues that doing so “would imply that the vaccine is ineffective, which is not the case.” The government is probing whether the deaths of three children were tied to the vaccine, which can raise the risk of severe disease in people who were not exposed to the virus. Sanofi agreed to reimburse the Philippines $29 million for the cost of unused vaccine and to conduct serotesting of the approximately 830,000 children who were vaccinated.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy